Phaseline

Targets › DDB1

DDB1 (DNA damage-binding protein 1): drug programs, companies and trials

11 programs from 9 companies in 225 trials: 134 Phase 2, 57 Phase 1, 33 Phase 3, 1 Phase 4; Oncology, Hematology, Other; next expected readout Feb 2027.

Involved in DNA repair and protein ubiquitination, as part of the UV-DDB complex and DCX (DDB1-CUL4-X-box) complexes, respectively. Core component of the UV-DDB complex (UV-damaged DNA-binding protein complex), a complex that recognizes UV-induced DNA damage and recruits proteins of the nucleotide excision repair pathway (the NER pathway) to initiate DNA repair. (UniProt, Q16531)

Open in Phaseline: the race on DDB1, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
National Cancer Institute (NCI)Thalidomide
CRL4(CRBN) E3 ubiquitin ligase inhibitor
CRBN, DDB1, CUL4A, RBX1Phase 3DS Stage I Multiple Myeloma; Multiple MyelomaFeb 2027
IncyteLenalidomide
CRL4(CRBN) E3 ubiquitin ligase inhibitor; CRL4(CRBN) E3 ubiquitin ligase modulator
CRBN, DDB1, CUL4A, RBX1Phase 3Large B-Cell Lymphoma; Diffuse Large B-cell Lymphoma; Diffuse Large B Cell Lymphoma; Newly Diagnosed …Apr 2027
Beijing InnoCare Pharma TechLenalidomide
CRL4(CRBN) E3 ubiquitin ligase inhibitor; CRL4(CRBN) E3 ubiquitin ligase modulator
CRBN, DDB1, CUL4A, RBX1Phase 3DLBCLApr 2027
University of ArkansasThalidomide
CRL4(CRBN) E3 ubiquitin ligase inhibitor
CRBN, DDB1, CUL4A, RBX1Phase 3Multiple Myeloma; MyelomaAug 2027
Bristol-Myers SquibbIberdomide
CRL4(CRBN) E3 ubiquitin ligase modulator
CRBN, DDB1, CUL4A, RBX1Phase 3Multiple Myeloma; Lymphoma, B-Cell; Newly Diagnosed Multiple Myeloma; Smoldering Plasma Cell Myeloma …Nov 2027
Shandong New Time PharmaceuticalPomalidomide (F182112)
CRL4(CRBN) E3 ubiquitin ligase inhibitor
CRBN, DDB1, CUL4A, RBX1Phase 3Relapsed or Refractory Multiple Myeloma (RRMM); Relapsed or Refractory Multiple Myeloma; Systemic Lupus Erythematosus (SLE); Multiple Myeloma …Dec 2027
CellCentricPomalidomide (CCS1477)
CRL4(CRBN) E3 ubiquitin ligase inhibitor
CRBN, DDB1, CUL4A, RBX1Phase 3Multiple Myeloma RefractoryNov 2029
RocheLenalidomide
CRL4(CRBN) E3 ubiquitin ligase inhibitor; CRL4(CRBN) E3 ubiquitin ligase modulator
CRBN, DDB1, CUL4A, RBX1Phase 3Relapsed or Refractory Follicular Lymphoma; Follicular LymphomaDec 2029
National Institute of Blood and Marrow Transplant (NIBMT), PakistanThalidomide
CRL4(CRBN) E3 ubiquitin ligase inhibitor
CRBN, DDB1, CUL4A, RBX1Phase 2Fetal Hemoglobin–
RocheIberdomide (CC-220)
CRL4(CRBN) E3 ubiquitin ligase modulator
CRBN, DDB1, CUL4A, RBX1Phase 1Multiple Myeloma; Non-Hodgkin LymphomaJul 2028
Bristol-Myers SquibbIberdomide (BMS-986382)
CRL4(CRBN) E3 ubiquitin ligase modulator
CRBN, DDB1, CUL4A, RBX1Phase 1Multiple MyelomaAug 2028

Conditions

Multiple Myeloma (54) Plasma Cell Myeloma (7) Follicular Lymphoma (6) Mantle Cell Lymphoma (6) DLBCL (5) Recurrent Multiple Myeloma (4) Diffuse Large B-cell Lymphoma (4) DS Stage I Multiple Myeloma (4) Multiple Myeloma in Relapse (4) Myeloma (3) Fetal Hemoglobin (3) Smoldering Plasma Cell Myeloma (3)

Modalities

mixed (8), small molecule (3)

Companies

Bristol-Myers Squibb (2) Roche (2) University of Arkansas (1) National Institute of Blood and Marrow Transplant (NIBMT), Pakistan (1) Incyte (1) National Cancer Institute (NCI) (1) Shandong New Time Pharmaceutical (1) Beijing InnoCare Pharma Tech (1) CellCentric (1)

Related targets

CRBN (11) CUL4A (11) RBX1 (11)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.